NONOF
Novo Nordisk A/S Class B · OTC:NONOF
39.45 USD0.4812 +1.23%
Novo Nordisk A/S Class B (OTC:NONOF) last traded at 39.45 USD, up 1.23% on the day. Over the past year the stock is down 21.10%. Its 52-week range is 34.00 to 64.75. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open39.75
Day range39.30 – 39.90
52-week range34.00 – 64.75
Volume12.29 K
Average volume (10 days)46.04 K
Market cap174.88 B
P/E9.88
EPS (TTM)3.99
Dividend yield4.40%
Beta (1 year)0.4821
Revenue (TTM)50.21 B
Employees68.79 K
Performance
+0.29%1 week
+3.79%1 month
−16.79%3 months
−11.09%6 months
−23.02%Year to date
−21.10%1 year
Technical rating
Neutral
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
45.80 USD
The average 1-year price target, +16.09% from the last price. See the forecast
Latest headlines
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
- Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.